Safety and Efficacy of GRT6005 in Pain Due to Diabetic Polyneuropathy
A Randomized 4-week Phase IIa Trial Evaluating the Efficacy, Safety, and Tolerability of GRT6005, a New Centrally Acting Analgesic, in Subjects With Pain Due to Diabetic Polyneuropathy.
Sponsor: Forest Laboratories
Listed as NCT01347671, this PHASE2 trial focuses on Diabetic Neuropathies and Pain and remains completed. Sponsored by Forest Laboratories, it has been updated 8 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Nov 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Nov 2019 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
May 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Forest Laboratories
- Tris Pharma, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aschaffenburg, Germany , Bad Oeynhausen, Germany , Berlin, Germany , Bucharest, Romania , Dresden, Germany , Hamburg, Germany , Hanover, Germany , Heidelberg, Germany , Kiel, Germany , Lübeck, Germany and 8 more locations